Skip to main content
Advertisement
Advertisement
RARE
RARE logo
Ultragenyx Pharmaceutical Inc.
17.22
USD
Sponsored
-0.51
-2.88%
Nov 19, 15:59 UTC -5
Closed
exchange

After-Market

17.02

-0.20
-1.13%

Ultragenyx Pharmaceutical Inc. (RARE) Earnings

RARE Earnings Reports

Positive Surprise Ratio

RARE beat 21 of 44 last estimates.

48%

Next Report

Date of Next Report
Feb 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
$228.28M
/
-$0.51
Implied change from Q3 26 (Revenue/ EPS)
+31.96%
/
-55.65%
Implied change from Q4 25 (Revenue/ EPS)
+10.28%
/
-60.47%

Ultragenyx Pharmaceutical Inc. earnings per share and revenue

On Nov 03, 2026, RARE reported earnings of -1.15 USD per share (EPS) for Q3 26, missing the estimate of -1.13 USD, resulting in a -1.83% surprise. Revenue reached 173.00 million, compared to an expected 186.78 million, with a -7.38% difference. The market reacted with a +3.19% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.51 USD, with revenue projected to reach 228.28 million USD, implying an decrease of -55.65% EPS, and increase of 31.96% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Invivyd, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+26.47%
logo
Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%
logo
Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q1 27
Estimate
-$0.26
Actual
-$0.20
Surprise
+23.61%
logo
Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%
logo
Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%
logo
Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%
logo
Lantern Pharma Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.81
Surprise
-126.89%
logo
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
logo
Pulmatrix, Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-
Actual
-$0.34
Surprise
-
FAQ
For Q3 2026, Ultragenyx Pharmaceutical Inc. reported EPS of -$1.15, missing estimates by -1.83%, and revenue of $173.00M, -7.38% below expectations.
The stock price moved up 3.19%, changed from $16.63 before the earnings release to $17.16 the day after.
The next earning report is scheduled for Feb 10, 2027.
Based on -- analysts, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$0.51 and revenue of $228.28M for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement